Skip to main content
. Author manuscript; available in PMC: 2024 Oct 1.
Published in final edited form as: Eur Urol Oncol. 2023 Apr 20;6(5):516–524. doi: 10.1016/j.euo.2023.03.008

Table 1 –

Patient characteristics for pretreatment cfDNA analysis

Total patients (N = 72) Responder (R) (N = 37) Nonresponder (NR) (N = 35) p value
Sex (male/female) 32/5 30/5 >0.9
Age, median (first to third quartile) 62.7 (55.7–68.9) 65.9 (62.0–69.4) 0.2
Clinical stage (T2/T3 or T4a) 34/3 29/6 0.3
ECOG performance status (0/1) 28/9 26/9 >0.9
Treatment arms (ddMVAC + CYST/GC + CYST) 22/15 15/20 0.2
cfDNA concentration (ng/7.5 ml), median (first to third quartile) 85.3 (62.5–147.9) 113.4 (75.0–141.0) 0.3

cfDNA = cell-free DNA; CYST = cystectomy; ddMVAC = dose-dense methotrexate, vinblastine, adriamycin, and cisplatin; ECOG = Eastern Cooperative Oncology Group; GC = gemcitabine and cisplatin.